20亿美元！Tempus押注的AI制药，买了一款中国药
Ranking
Overall
71
Content
80
Popularity
N/A
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - AI drug developer Pathos AI licensed ex-China rights to Jiangsu Alphamab’s bispecific ADC JSKN016 in a deal worth up to $2.093 billion, expanding its oncology pipeline alongside an AstraZeneca PROTAC asset.
- Pathos will pay $125 million upfront for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate.
- JSKN016 has begun Phase III dosing for triple-negative breast cancer.
- Pathos also acquired early clinical-development rights to AstraZeneca’s oral PROTAC degrader AZD4241 for ER+/HER2− breast cancer.
- The Tempus AI-linked company is developing the PathOS multimodal oncology foundation model and a multi-agent platform called Foundry.
Sources (1)
20亿美元！Tempus押注的AI制药，买了一款中国药
Public signals
N/A
TL;DR - AI drug developer Pathos AI licensed ex-China rights to Jiangsu Alphamab’s bispecific ADC JSKN016 in a deal worth up to $2.093 billion, expanding its oncology pipeline alongside an AstraZeneca PROTAC asset.
- Pathos will pay $125 million upfront for JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate.
- JSKN016 has begun Phase III dosing for triple-negative breast cancer.
- Pathos also acquired early clinical-development rights to AstraZeneca’s oral PROTAC degrader AZD4241 for ER+/HER2− breast cancer.
- The Tempus AI-linked company is developing the PathOS multimodal oncology foundation model and a multi-agent platform called Foundry.